Triflupromazine

Triflupromazine
Clinical data
AHFS/Drugs.comMicromedex Detailed Consumer Information
MedlinePlusa600010
ATC code
Legal status
Legal status
Identifiers
IUPAC name
  • N,N-dimethyl-3-[2-(trifluoromethyl)-10H-phenothiazin-10-yl]propan-1-amine
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.005.158
Edit this at Wikidata
Chemical and physical data
FormulaC18H19F3N2S
Molar mass352.42 g·mol−1
3D model (JSmol)
SMILES
  • CN(C)CCCN1c2ccccc2Sc2ccc(cc12)C(F)(F)F
InChI
  • InChI=1S/C18H19F3N2S/c1-22(2)10-5-11-23-14-6-3-4-7-16(14)24-17-9-8-13(12-15(17)23)18(19,20)21/h3-4,6-9,12H,5,10-11H2,1-2H3 ☒N
  • Key:XSCGXQMFQXDFCW-UHFFFAOYSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Triflupromazine (Vesprin) is an antipsychotic medication of the phenothiazine class. Among different effects of triflupromazine indication for use of this drug is severe emesis and severe Hiccups.[1] Due to its potential side effects (triflupromazine has higher risk for side effects than many other antipsychotics) it is not gold standard in antiemetic therapy.

Serious side effects of triflupromazine can be akathisia and tardive dyskinesia as well as the rare, but potentially fatal, neuroleptic malignant syndrome.

References

  1. ↑ Drug bank.ca.



This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.